uniQure N.V. (0EE0.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
uniQure N.V.
Address
Paasheuvelweg 25
Amsterdam, NH 1105 BP
Netherlands (Kingdom of the)
Phone
31 20 240 6000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
221
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Matthew Craig Kapusta | Chief Executive Officer & Executive Director | 1.05M | 1972 |
| Jeannette Potts | Chief Legal & Compliance Officer and Corporate Secretary | 712,827 | 1962 |
| Richard Porter | Chief Business & Scientific Officer | 732,169 | 1968 |
| Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site | 759,950 | 1973 |
| Walid Abi-Saab | Chief Medical Officer | 945,278 | 1965 |
| Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 0 | N/A |
| Chiara Elizabeth Russo | Senior Director of Investor Relations | 0 | N/A |
| Erin Boyer | Chief People & Culture Officer | 0 | N/A |
| Kylie O'Keefe | Chief Customer & Strategy Officer | 0 | 1985 |
| Tamara Tugal | Business Development Director | 0 | N/A |
| Amin Abujoub | Chief Technical Operations Officer | 0 | N/A |
Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
